Sandoz and Biocon strike global biosimilars alliance
Sandoz has formed an exclusive global alliance with Biocon to co-develop and market “next-generation biosimilars” in the immunology and oncology arenas. Neither the number nor the identity of the targeted molecules have been disclosed, but Biocon said the partnership covered “multi-billion dollar opportunities” through molecules in “early stages of development”. The partners will “share responsibility for end-to-end development, manufacturing, and global regulatory approvals”, and will split costs and profits from marketing the biosimilars equally.
You may also be interested in...
As Sandoz reported its second-quarter financial results, the firm revealed details of a previously unannounced development program for biosimilar denosumab.
Leading Indian biotech firm Biocon has got the green light for a biosimilar manufacturing facility from Europe’s drug regulator, paving the way for the company’s growing biosimilars portfolio to gain greater European market access.
Sandoz has a place within Novartis as a more autonomous unit, the Swiss group’s CEO Vas Narasimhan says. But the generics and biosimilars division will have to sharpen up, aided by a 7% workforce cut.